

4th Announcement

Angiogenesis: A Key Target in Oncology

Budapest, Hungary

Friday, September 10 – Saturday, September 11, 2010

Chairs:

Prof Eric Van Cutsem and Prof Emile Voest

Scientific Course Coordinator:

M. Aapro

Register now at: www.etcho.org

Support from Bayer HealthCare and Roche



Bayer HealthCare
Bayer Schering Pharma



*In collaboration with
the EORTC Group*



AGENDA

FRIDAY SEPTEMBER 10, 2010

Registration opens at 10:00 am. Lunch buffet available from 12:00.

13:30-13:40 *Introduction*

Eric Van Cutsem, Emile Voest, Matti Aapro

13:40-15:30 SESSION I: Basic Knowledge

Session chair: Eric Van Cutsem

13:40-14:05 *Understanding the process of angiogenesis and cancer*

Peter Carmeliet

14:10-15:00 *How long should Angiogenesis inhibitors be administered?*

20' *Pre-clinical data*

15' *Clinical data*

15' *Clinical case*

Anil Bagri

Emile Voest

Martin Reck

15:05-15:25 *Preclinical topic – Resistance to angiogenesis inhibitors*

Luisa Arispa

15:30-16:00 *Coffee break*

16:00-17:00 Session II: Breast & Gynaecological Tumors

Session chair: Matti Aapro

16:00-16:15 *Angiogenesis inhibition in Breast cancer*

Rebecca Dent

16:20-16:35 *Angiogenesis inhibition in Ovarian cancer*

Sandro Pignata

16:40-16:55 *Cases in Breast cancer*

Rebecca Dent / Matti Aapro

17:00-18:00 Session III: Genito-urinary Cancers

Session chair: Emile Voest

17:00-17:15 *Angiogenesis inhibition in Prostate cancer*

Winald Gerritsen

17:20-17:35 *Why are angiogenesis inhibitors so active in RCC?*

Peter Mulders

17:40-17:55 *How to choose between the different available agents in RCC?*

Joaquim Bellmunt

18:00-18:05 *Adjourn day 1*

SATURDAY SEPTEMBER 11, 2010

08:15-09:45 **SESSION IV: Gastrointestinal Cancers**

Session chair: Eric Van Cutsem

08:15-09:05 *Angiogenesis inhibition in CRC*

15' *Optimal strategy with angiogenesis inhibitors in CRC*

Eric Van Cutsem

15' *Multi-drug combination strategies in CRC:
what can we combine with angiogenesis inhibitors?*

Alfredo Carrato

20' *Debate*

09:05-09:20 *Angiogenesis inhibition in Gastric cancer*

Arnaud Roth

09:25-09:40 *Angiogenesis inhibition in HCC*

Michel Ducreux

09:45-10:25 **Session V: Other Tumors**

Session chair: Emile Voest

09:45-10:00 *Angiogenesis inhibition in Glioblastoma*

Ulrik Lassen

10:05-10:20 *Angiogenesis inhibition in Lung cancer*

Jürgen Wolf

10:25-10:55 *Coffee break*

11:00-11:30 *Keynote Lecture: Impact of our understanding of angiogenesis
on present and future cancer treatment*

István Láng

11:30-12:40 **Session VI: Imaging Tools for Determining the Activity of Angiogenesis Inhibitors**

Session chair: Emile Voest

11:30-11:50 *Ultrasound + MRI*

Nathalie Lassau

11:55-12:15 *Biomarkers*

Francesco Bertolini

12:20-12:35 *Is there a place for PET with FDG or new tracers in the evaluation of
the activity of Angiogenesis Inhibitors?*

Ingrid Dijkgraaf

12:40-13:45 **Session VII: General Management of Angiogenesis Inhibitors**

Session chair: Eric Van Cutsem

12:40-12:55 *Surgery after angiogenesis inhibitors*

Oliver Stöltzing

13:00-13:15 *Angiogenesis inhibition in combination with Radiotherapy*

Christopher Willett

13:20-13:40 *Practical management of anti-angiogenesis therapies*

TBC

13:45-14:00 *Learning assessments: Attendees answer 15 questions based on the course*

TBC

14:00-14:10 *Certificate delivery*

14:10-15:10 *Lunch buffet*

Angiogenesis: A Key Target in Oncology

Course Objectives

This course will provide the background for oncologists to understand the basic science and the clinical achievements in angiogenesis related cancer therapy.

This is intended to be a practice oriented course, helping decision making processes for the clinician. Participants will have an opportunity to discuss patient case studies and interact with experts as well as receive updates on the latest data and advances in this field.

This is a teaching course in cooperation with the EORTC Group.



European Society for Medical Oncology

The course has been certified with
8 ESMO-MORA points Category 1.

Each participant will receive a certificate of attendance stating the relevant number of credits obtained during the conference.

Venue

Hotel Novotel Budapest Congress
Alkotás utca 63-67
1123 Budapest, Hungary

Target Audience

Physicians, Medical Oncologists and
Other Healthcare Professionals

Course Secretariat and Logistics

ETICHO

Scheveningseweg 56 F
2517 KW The Hague
The Netherlands

Tel: +31 70 30 67 200

Fax: +31 70 33 18 442

email: info@eticho.org